So says reader BuriedTreasure “Appointing PKF Littlejohn, auditors for all sorts of scallywags, is never a positive move" with regard to today’s news from Probiotix (PBX). But he is wrong. Do not get me wrong, PKF does act for all sorts of scallywags but that is not the same as saying that all its clients are scallywags.
Probiotics company ProBiotix Health (AQSE - PBX) has announced its results for the first half of the 2026 calendar year and that it “has continued to expand its global footprint, with the APAC region again proving a particularly strong market… partnership with Kemin continues to develop, leading to increasing demand in China”. The key thing is that it is profitable, unlike the other 2 dogs in the OptiBiotix stable, and that is why the shares are a compelling buy at a 9.5p share price, £15 million market cap.
ProBiotix Health (AQSE:PBX) has followed a “New Strategic Alliance in Spain and Portugal” with now also a “New Partnership Agreement in Slovakia”. With these further agreements, what’s the outlook from the valuation at a current 7.25p share price, £11.5 million market cap?
Probiotics for use in dietary supplements company ProBiotix Health (PBX) has announced its results for the 2025 calendar year and that, “with a highly scalable business, record new enquiries, and a significant market to address, we view the future with considerable confidence”. The following is why that also suggests considerable upside from a current 8p share price.
Having recently been steady at 7.75p, shares in ProBiotix Health (AQSE - PBX) were earlier falling back quite heavily before a “Statement re Share Price Movement” from the company. What reassurance does it provide?
ProBiotix Health (PBX), a life sciences business developing probiotics to support cardiometabolic health, has issued a “Trading Update” including ‘highlighting’ 2025 calendar year sales up 45% to £2.72 million and a “record Q1 2026 order book +110% at £1.3m”. How’s the performance and outlook relative to the valuation at an 8.25p share price?
ProBiotix Health (AQSE - PBX) has announced a “new commercial partnership in Australia” for cardiometabolic health and emphasises “the nutraceutical segment addressing cardiometabolic health is experiencing strong growth across all the target regions, with market expansion rates of 8-10% annually, driven by rising lifestyle-related health concerns and demand for clinically supported, science-based preventive product solutions”. This adds to ProBiotix’s excitement about its future sales potential.
ProBiotix Health (AQSE - PBX) has served up two snippets of news both of which are positive in a small way. We have spoken to the company and now publish new forecasts.
ProBiotix Health (AQSE - PBX) has announced its results for the first half of 2025 emphasising “accelerating consumer acceptance” and a market of “growing demand for effective, science-backed health solutions”. The following is why its performance and outlook combination suggest strong upside potential from the current 7.75p share price.
Adam Reynolds and Steen Anderson said they would buy shares in Probiotix (PBX) after a cleansing trading statement. But they have not.
ProBiotix Health (PBX) has issued a trading update noting still a loss but that it is significantly reduced on revenue up by 33% and with an “order book at record level which augurs well for H2”. The shares are up to 10p, including from a 7p offer price tip just last week, but the following is why there looks more to go for.
Probiotics life sciences company ProBiotix Health (AQSE - PBX) has announced its results for the 2024 calendar year including highlighting “solid financial position with cash balances totalling £1.65m (2023: £1.50m)” and “current trading very strong with a record order book. Outlook for 2025 and beyond remains positive”. The following is why we consider it suggests significant upside from an up to 8p share price.
We first tipped Probiotix (AQSE - PBX) at a 6p offer last October. Then it was a tip of the year just after Christmas at a 7p offer. The shares have recently closed at 9.5p-11.5p and things look to be getting further better.
